RxDoctor Payments Data

Nicolas Mungo, MD

Endocrinology, Diabetes & Metabolism · Brookfield, WINPI 1245627991

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $8,566 of the $13,585 with a category attached, or 63.1%. Amgen accounts for 74.5% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $9,284, 6.1 times the $1,529 reported in 2019.

$13,585in general payments, 2019–2025

Across 101 payments — averaging $134.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$10K
  • Novo Nordisk$2K
  • Halozyme Inc$221
  • Abbott$217
  • Lilly USA, LLC$196
  • Corcept Therapeutics$151
  • plus $676 from 8 others

What the payments were for

  • Speaking & faculty fees$8,56663%
  • Travel & lodging$1,97515%
  • Food & beverage$2,84621%
  • Education$1991%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,585 in reported general payments places this provider in the 85th percentile of 127 endocrinology, diabetes & metabolism providers in Wisconsin.

See all endocrinology, diabetes & metabolism providers in Wisconsin

Medicare billing

Part B allowed, 2024
$82,942
Medicare patients
314
Services billed
6,337

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide225$275,513
JardianceEmpagliflozin84$124,447
MounjaroTirzepatide104$117,516
GenotropinSomatropin21$53,316
TrulicityDulaglutide18$32,594
Tresiba Flextouch U-100Insulin Degludec52$24,019
JanuviaSitagliptin Phosphate23$21,428
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$14,198
SynthroidLevothyroxine Sodium173$13,929
XyostedTestosterone Enanthate19$11,556
Lantus SolostarInsulin Glargine,hum.Rec.Anlog73$11,197
Testosterone53$8,517
Tresiba Flextouch U-200Insulin Degludec12$7,607
Levothyroxine Sodium730$6,569
Humalog Kwikpen U-100Insulin Lispro31$6,374

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,999$275,513225 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$196$154,130140 claims
Boehringer IngelheimJardiance$81$124,44784 claims
Antares Pharma, Inc.Xyosted$138$11,55619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 127 endocrinology, diabetes & metabolism providers in Wisconsin.

Other endocrinology, diabetes & metabolism in Brookfield

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →